Roche Holding AG said an experimental breast-cancer treatment will get an expedited review from US regulators after showing it helped patients live longer without the disease progressing. The ...

Roche RHHBY announced that the FDA has approved pipeline candidate, inavolisib, for the treatment of breast cancer ... based regimen was granted Priority Review by the FDA. It was also granted ...

Roche RHHBY obtained a Breakthrough Therapy Designation for its investigational oral therapy inavolisib for treating adult breast cancer patients in the United States. The FDA granted this ...

Basel, 29 May 2024 - Roche (SIX ... or metastatic breast cancer, following recurrence on or within 12 months of completing adjuvant endocrine treatment. The Priority Review is based on the ...

Roche Holding said the U.S. Food and Drug Administration granted priority review to the company's new drug application for inavolisib as a treatment for a type of advanced breast cancer.

HER2-negative locally advanced or metastatic breast cancer that recurred (came back) on or within 12 months of postsurgical endocrine treatment. Roche, the manufacturer of inavolisib, announced the ...